Verdiva Bio appoints former Metsera CMO Steve Marso as it nears key obesity pill readouts
read at Endpoints ↗Neutral
Verdiva Bio, a developer of a long-acting oral obesity treatment, announced the appointment of Steve Marso as its chief medical officer.
Marso joins from Metsera, a biotech that pursued similar GLP-1 based technology and was recently acquired for $10 billion.
The leadership change comes as Verdiva prepares for pivotal clinical readouts that could determine the future of its obesity pill program.
Industry observers view the hire as a move to bring experienced regulatory and development expertise to the company ahead of those critical data releases.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near”
read at Endpoints ↗90 words · retrieved Jul 23
comments(0)
5-min edit window · permanent after that